Die perinatale Therapie mit Glukokortikosteroiden: Zeit zum Umdenken[1]

Zusammenfassung

Glukokortikosteroide werden sowohl prä- als auch postnatal zur Senkung der pulmonalen Morbidität Frühgeborener eingesetzt. Ein einmaliger pränataler Steroidzyklus reduziert die Mortalität Frühgeborener sowie die Häufigkeit des Atemnotsyndroms und der Hirnblutung. Die Verabreichung repetitiver Behandlungszyklen kann jedoch möglicherweise einen ungünstigen Einfluss auf die Hirnentwicklung haben. Nachuntersuchungsstudien von Kindern mit mehrfachen pränatalen Steroidzyklen sind erforderlich. Die Art des verwendeten Steroids ist offenbar ebenfalls von Bedeutung für die zerebrale Morbidität von Frühgeborenen, die derzeitige Datenlage favorisiert Betamethason gegenüber Dexamethason. Postnatal werden Steroide zur Prophylaxe oder Therapie der bronchopulmonalen Dysplasie (BPD) verabreicht. Neuere Untersuchungen haben jedoch gezeigt, dass die Behandlung der BPD mit Dexamethason zu einer erhöhten Rate an Zerebralparesen führt. Die postnatale Behandlung der BPD mit Steroiden sollte auf lebensbedrohliche Situationen begrenzt werden.

Glucocorticosteroids are administered antenatally and postnatally to decrease pulmonary morbidity of preterm neonates. One course of antenatal corticosteroids decreases mortality, and the frequency of respiratory distress syndrome and intraventricular hemorrhage. However, multiple courses may be associated with impaired brain development. Follow-up studies are needed to assess long-term consequences. The use of betamethasone may be of advantage compared to dexamethasone. Postnatally, steroids are given to treat or prevent bronchopulmonary dysplasia (BPD). However, recent studies have shown that treatment with dexamethasone increases the rate of cerebral palsy in preterm infants. Postnatal treatment of BPD with steroids should be restricted to life-threatening situations.

Schlüsselwörter

Perinatale Steroidtherapie - Glukokortikoide - Dexamethason - Betamethason - bronchopulmonale Dysplasie

Key words

Perinatal corticosteroids - glucocorticosteroids - dexamethasone - betamethasone - bronchopulmonary dysplasia

1 Eingang: 7. 3. 2001
Angenommen nach Revision: 9. 4. 2001

Literatur

1 Eingang: 7. 3. 2001
Angenommen nach Revision: 9. 4. 2001

• 01 Crowley  P A. Antenatal corticosteroid therapy: A meta-analysis of the randomized trials 1972 to 1994.  Am J Obstet Gynecol. 1995;  83 483-494
• 02 Sauerwald  A, Rath  W. Lungenreifetherapie mit Glukokortikoiden bei drohender Frühgeburt.  Z Geburtsh Neonatol. 2000;  204 203-209
• 03 Ballard  P L, Granberg  P, Ballard  R A. Glucocorticoid levels in maternal and cord serum after prenatal betamethasone therapy to prevent respiratory distress syndrome.  J Clin Invest. 1975;  56 1548-1554
• 04 Whitelaw  A, Thoresen  M. Antenatal steroids and the developing brain.  Arch Dis Child Fetal Neonatal Ed. 2000;  83 F154-F157
• 05 Barres  B A, Lazar  M A, Raff  M C. A novel role for thyroid hormone, glucocorticoids, and retinoic acid in timing oligodendrocyte development.  Development. 1994;  120 1097-1108
• 06 Gumbinas  M, Oda  M, Huttenlocher  P. The effects of corticosteroids on myelination of the developing rat brain.  Biol Neonate. 1973;  22 355-366
• 07 Carlos  R Q, Seidler  F J, Slotkin  T A. Fetal dexamethasone exposure alters macromolecular characteristics of rat brain development: A critical period for regionally selective alterations?.  Teratoloy. 1992;  46 45-59
• 08 Slotkin  T A, Lappi  S E, McCook  E C, Tayyeb  M I, Eylers  J P, Seidler  F J. Glucocorticoids and the development of neuronal function: Effects of prenatal dexamethasone exposure on central noradrenergic activity.  Biol Neonate. 1992;  61 326-336
• 09 Benesova  O, Pavlik  A. Perinatal treatment with glucocorticoids and the risk of maldevelopment of the brain.  Neuropharmacology. 1989;  28 89-97
• 10 Cotterrell  M, Balazs  R, Johnson  A. Effects of corticosteroids on the biochemical maturation of rat brain: postnatal cell formation.  J Neurochem. 1972;  19 2151-2167
• 11 Huang  W L, Beazley  L D, Quinlivan  J A, Evans  S F, Newnham  J P, Dunlop  S A. Effect of corticosteroids on brain growth in fetal sheep.  Obstet Gynecol. 1999;  94 213-218
• 12 Quinlivan  J A, Dunlop  S ASF, Newnham  J P, Evans  S F, Beazley  L D. Repeated, but not single maternal administration of corticosteroids delays myelination in the brain of fetal sheep.  Prenatal and Neonatal Medicine. 1999;  4 47-55
• 13 French  N P, Hagan  R, Evans  S F, Godfrey  M, Newnham  J P. Repeated antenatal corticosteroids: Size at birth and subsequent development.  Am J Obstet Gynecol. 1999;  180 114-121
• 14 Hack  M, Breslau  N, Weissman  B, Aram  D, Klein  N, Borawski  E. Effect of very low birth weight and subnormal head size on cognitive abilities at school age.  N Engl J Med. 1991;  325 231-237
• 15 NIH Consensus Development Panel .Effects of corticosteroids for fetal maturation on perinatal outcomes. JAMA 1995 273: 413-417
• 16 Mc Arthur  B A, Howie  R N, Dezoete  J A, Elkins  J. School progress and cognitive development of 6 year-old children whose mothers were treated antenatally with betamethasone.  Pediatrics. 1982;  70 99-105
• 17 Doyle  L W, Ford  G W, Rickards  A L, Kelly  E A, Davis  N M, Callanan  C, Olinsky  A. Antenatal corticosteroids and outcome at 14 years of age in children with birth weight less than 1501 grams.  Pediatrics. 2000;  106 e2
• 18 Dessens  A, Smolders-de Haas  H, Koppe  J G. Twenty-year follow-up of antenatal corticosteroid treatment.  Pediatrics. 2000;  105 e77
• 19 Rennie  J M, Wheater  M, Cole  T J. Antenatal steroid administration is associated with an improved chance of intact survival in preterm infants.  Eur J Pediatr. 1996;  155 576-579
• 20 Baud  O, Foix-Helias  L, Kaminski  M, et al. Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants.  N Engl J Med. 1999;  341 1190-1196
• 21 Ewerbeck  H, Helwig  H. Treatment of idiopathic respiratory distress syndrome with large doses of corticoids.  Pediatrics. 1972;  49 467-468
• 22 Baden  M, Bauer  C R, Colle  E, Klein  G, Taeusch  H W, Stern  L. A controlled trial of hydrocortsisone therapy in infants with RDS.  Pediatr. 1972;  50 526-534
• 23 Mammel  M C, Green  T P, Johnson  D A, Thompson  T R. Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia.  Lancet. 1983;  1 1356-1358
• 24 Avery  G B, Fletcher  A B, Kaplan  M, Brudno  D S. Controlled trial of dexamethasone in respirator-dependent infants with bronchopulmonary dysplasia.  Pediatrics. 1985;  75 106-111
• 25 Harkavy  K L, Scanlon  J W, Chowdhry  P K, Grylack  L J. Dexamethasone therapy for chronic lung disease in ventilator and oxygen-dependent infants: a controlled trial.  J Pediatr. 1989;  115 979-993
• 26 Cummings  J J, D'Eugenio  D B, Gross  S J. A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia.  N Engl J Med. 1989;  320 1505-1510
• 27 Halliday  H L. Clinical trials of postnatal corticosteroids: inhaled and systemic.  Biol Neonate. 1999;  76 Suppl 29-40
• 28 Groneck  P, Soditt  V, Bläker  F. Klinische Auswirkungen der Dexamethasontherapie bei Frühgeborenen mit hohem Risiko für eine bronchopulmonale Dysplasie.  Monatsschr Kinderheilkd. 1994;  142 279-284
• 29 Groneck  P, Reuss  D, Götze-Speer  B, Speer  C P. Effects of dexamethasone on chemotatic activity and inflammatory mediators in tracheobronchial aspirates of preterm infants at risk for chronic lung disease.  J Pediatr. 1993;  122 938-944
• 30 Ng  P C. The effectiveness and side effects of dexamethasone in preterm infants with bronchopulmonary dysplasia.  Arch Dis Childh. 1993;  68 330-336
• 31 Shinwell  E S, Karplus  M, Zamora  E et al. Failure of early postnatal dexamethasone to prevent chronic lung disease in infants with respiratory distress syndrome.  Arch Dis Childh Fetal Neonatal Ed. 1996;  74 F33-F37
• 32 Shinwell  E S, Karplus  M, Reich  D, Weintraub  Z, Blazer  S, Bader  D et al. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy.  Arch Dis Child Fetal Neonatal Ed. 2000;  83 F177-F181
• 33 Yeh  T F, Lin  Y J, Huang  C C, Chen  Y J, Lin  C H, Lin  H C, Hsieh  W S, Lien  Y J. Early dexamethasone therapy in preterm infants: a follow up study.  Pediatrics. 1998;  101 E7
• 34 O'Shea  T M, Kothadia  K L, Klinepeter  K L, et al. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age.  Pediatrics. 1999;  104 15-21
• 35 Sapolsky  R M. Corticosteroids and hippocampal damage.  Trends Neurosci. 1987;  10 346-349
• 36 Wooley  C, Gould  E, McEwen  B. Exposure to excess glucocorticoids alters dendritic morphology of adult hippocampal pyramidal neurons.  Brain Res. 1990;  531 225
• 37 Murphy  B P, Inder  T E, Hüppi  P, Warfield  S, Zientara  G P, Kikinis  L, Jolesz  F A, Volpe  J J. Impaired cerebral cortical grey matter growth after treatment with dexamethasone for neonatal chronic lung disease.  Pediatrics. 2001;  107 217-221
• 38 Halliday  H L, Ehrenkranz  R A. Early (< 96 hours) postnatal corticosteroids for preventing chronic lung disease in preterm infants.  Cochrane Database Syst Rev. 2000;  (2) pCD001146
• 39 Halliday  H L, Ehrenkranz  R A. Moderately early (7 - 14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants.  Cochrane Database Syst Rev. 2000;  (2) pCD001144
• 40 Halliday  H L, Ehrenkranz  R A. Delayed (> 3 weeks) postnatal corticosteroids for preventing chronic lung disease in preterm infants.  Cochrane Database Syst Rev. 2000;  (2) pCD001145
• 41 Baud  O, Zupan  V, Lacaze-Masmontail  T, Dehan  M. Neurological adverse effects of early postnatal dexamethasone in very preterm infants.  Arch Dis Childh Fetal Neonatal Ed. 1999;  80 F159
• 42 André  P, Thebaud  B, Odievre  M H, Razafimahefa  H, Zupan  V, Dehan  M, Lacaze-Masmonteil  T. Methylprednisolon, an alternative to dexamethasone in very preterm infants at risk of chronic lung disease.  Intensive Care Med. 2000;  26 1496-1500